What is Leede Financial’s Estimate for ONCY FY2025 Earnings?

Oncolytics Biotech Inc. (NASDAQ:ONCY) – Leede Financial boosted their FY2025 earnings per share (EPS) estimates for Oncolytics Biotech in a note issued to investors on Monday, March 10th. Leede Financial analyst D. Loe now forecasts that the company will post earnings of ($0.28) per share for the year, up from their prior forecast of ($0.29). The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.28) per share. Leede Financial also issued estimates for Oncolytics Biotech’s FY2026 earnings at ($0.28) EPS, FY2027 earnings at ($0.26) EPS, FY2028 earnings at ($0.26) EPS and FY2029 earnings at ($0.09) EPS.

A number of other equities analysts have also commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Oncolytics Biotech in a research note on Monday. Raymond James upgraded shares of Oncolytics Biotech to a “moderate buy” rating in a research note on Thursday, November 14th. Royal Bank of Canada lowered their target price on Oncolytics Biotech from $6.00 to $5.00 and set an “outperform” rating on the stock in a research note on Monday. Finally, Maxim Group reduced their price objective on shares of Oncolytics Biotech from $5.00 to $3.00 and set a “buy” rating for the company in a research note on Monday. Three research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Oncolytics Biotech presently has a consensus rating of “Buy” and a consensus target price of $4.00.

Oncolytics Biotech Price Performance

ONCY stock opened at $0.62 on Thursday. The stock has a market cap of $53.27 million, a price-to-earnings ratio of -2.31 and a beta of 1.18. The company has a 50 day simple moving average of $0.77 and a 200 day simple moving average of $0.92. Oncolytics Biotech has a 1 year low of $0.58 and a 1 year high of $1.53.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ONCY. Vantage Point Financial LLC bought a new position in Oncolytics Biotech during the 4th quarter valued at approximately $27,000. National Bank of Canada FI lifted its stake in Oncolytics Biotech by 199.6% in the 4th quarter. National Bank of Canada FI now owns 64,479 shares of the company’s stock worth $60,000 after purchasing an additional 42,955 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Oncolytics Biotech by 59.6% in the 4th quarter. Geode Capital Management LLC now owns 66,939 shares of the company’s stock worth $61,000 after buying an additional 24,997 shares in the last quarter. Virtu Financial LLC bought a new position in Oncolytics Biotech during the fourth quarter valued at $90,000. Finally, International Assets Investment Management LLC lifted its stake in shares of Oncolytics Biotech by 15.0% during the 4th quarter. International Assets Investment Management LLC now owns 200,400 shares of the company’s stock worth $186,000 after acquiring an additional 26,069 shares during the last quarter. Institutional investors own 6.82% of the company’s stock.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.